Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Kevin Atchison"'
Autor:
Andrea M. Zuhl, Charles E. Nolan, Michael A. Brodney, Sherry Niessen, Kevin Atchison, Christopher Houle, David A. Karanian, Claude Ambroise, Jeffrey W. Brulet, Elizabeth M. Beck, Shawn D. Doran, Brian T. O’Neill, Christopher W. am Ende, Cheng Chang, Kieran F. Geoghegan, Graham M. West, Joshua C. Judkins, Xinjun Hou, David R. Riddell, Douglas S. Johnson
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-14 (2016)
Several β-secretase (BACE) inhibitors exhibit unexplained ocular toxicity in preclinical studies. Here the authors generate a clickable photoaffinity probe to interrogate off-targets in cells and animals, and identify inhibition of cathepsin D as a
Externí odkaz:
https://doaj.org/article/5dfe4a29e6af43a49ee6c24207abc513
Autor:
Alexei Protopopov, Tun Tun Lin, Andrew Hebert, Sukhvinder Sidhu, Lily Pao, Kevin Atchison, Adalis Maisonet, Tatiana Tolstykh, Dmitri Wiederschain, Jack Pollard, Sharad K. Sharma, Joachim Theilhaber, Mikhail Levit, Natalia Malkova, Sara Sara Sinicropi-Yao
Publikováno v:
Cancer Research. 81:1909-1909
Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related deaths worldwide, accounting for more than 700,000 deaths per year. Although transforming growth factor beta (TGF-β) can function as a tumor-suppressor in premalignant c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e177f918d538fc33e3ec1ba1524c451
https://doi.org/10.1158/1538-7445.am2021-1909
https://doi.org/10.1158/1538-7445.am2021-1909
Autor:
Felix Vajdos, Eric Benvenuti, Leanne M. Buzon, Brian T. O’Neill, Gabriela Barreiro, David Riddell, Kevin Atchison, Charles E. Nolan, Ashley Robshaw, Eric F. Johnson, Kevin D. Parris, Shawn D. Doran, Michael Aaron Brodney, Xinjun Hou, Luis Martinez-Alsina, Kimberly Lapham, Mei-Hui Hsu, Elizabeth Mary Beck, Christopher Ryan Butler, Kevin Ogilvie, Cathleen Gonzales, Lorraine F. Lanyon, Christopher John Helal
Publikováno v:
Journal of Medicinal Chemistry
A growing subset of β-secretase (BACE1) inhibitors for the treatment of Alzheimer's disease (AD) utilizes an anilide chemotype that engages a key residue (Gly230) in the BACE1 binding site. Although the anilide moiety affords excellent potency, it s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ded625eb28a2c9b897d6055a57557a14
https://doi.org/10.1021/acs.jmedchem.6b01451
https://doi.org/10.1021/acs.jmedchem.6b01451
Autor:
Judith A. Steen, Dinorah Jean-Gilles, Pieter Beerepoot, Naomi Klickstein, Bradley T. Hyman, Mark B. De Los Santos, Tarun V. Kamath, Renee Moore, Arthur Viode, Aurélien Lathuilière, Lori B. Chibnik, Matthew P. Frosch, Ryan C. Clark, Derek H. Oakley, Alberto Serrano-Pozo, Benjamin D. Moore, Fiona Elwood, Rudolph E. Tanzi, Diana L. Corjuc, Simon Dujardin, Analiese R. Fernandes, Matthew E. Kennedy, Patrick M. Dooley, Bianca T. Corjuc, Kristina Mullin, Caitlin Commins, Kevin Atchison
Publikováno v:
Nat Med
Nature medicine, Vol. 26, No 8 (2020) pp. 1256-1263
Nature medicine, Vol. 26, No 8 (2020) pp. 1256-1263
Alzheimer's disease (AD) causes unrelenting, progressive cognitive impairments, but its course is heterogeneous, with a broad range of rates of cognitive decline1. The spread of tau aggregates (neurofibrillary tangles) across the cerebral cortex para
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc7bb689b9606b3271da239615caaeaa
https://pubmed.ncbi.nlm.nih.gov/33514949
https://pubmed.ncbi.nlm.nih.gov/33514949
Autor:
Lori B. Chibnik, Benjamin D. Moore, Arthur Viode, Fiona Elwood, Tarun V. Kamath, Renee Moore, Patrick M. Dooley, Derek H. Oakley, Dinorah Jean-Gilles, Pieter Beerepoot, Alberto Serrano-Pozo, Diana L. Corjuc, Naomi Klickstein, Bradley T. Hyman, Kevin Atchison, Mark B. De Los Santos, Matthew P. Frosch, Aurélien Lathuilière, Judith A. Steen, Kristina Mullin, Analiese R. Fernandes, Matthew E. Kennedy, Caitlin Commins, Rudolph E. Tanzi, Simon Dujardin, Ryan C. Clark, Bianca T. Corjuc
Publikováno v:
Nature Medicine. 27:356-356
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::33a3649c37bbbd326c2a02b43cbbbbed
https://doi.org/10.1038/s41591-021-01251-7
https://doi.org/10.1038/s41591-021-01251-7
Autor:
Andrew Hebert, Jack Pollard, Sukhvinder Sidhu, Timothy R. Wagenaar, Kevin Atchison, Mikhail Levit, Alexei Protopopov, Dmitri Wiederschain, Adalis Maisonet, Ugur Sahin, Tatiana Tolstykh, Christian Hotz, Joachim Theilhaber, Natalia Malkova
Publikováno v:
Cancer Research. 80:4451-4451
Cancer immunotherapies with anti-PD-1/PD-L1 checkpoint blockade antibodies have revolutionized the treatment of a wide variety of malignancies. However, immunotherapy is ineffective in a significant subset of patients, or eventually results in the de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::296f8f089aa9b6b89bc11de8bd72750b
https://doi.org/10.1158/1538-7445.am2020-4451
https://doi.org/10.1158/1538-7445.am2020-4451
Autor:
Christopher John Helal, Kevin Atchison, Christopher Ryan Butler, Cathleen Gonzales, Ricardo Lira, Shawn D. Doran, Feng Pan, Felix Vajdos, Alison H. Varghese, Gabriela Barreiro, Michael Aaron Brodney, Jinlong Wang, Elizabeth Mary Beck, Luis Martinez-Alsina, Yong Zhang, Kevin D. Parris, David Riddell, Joseph Michael Young, Leanne M. Buzon, Ashley Robshaw, Kevin Ogilvie, Jason K. Dutra, Brian T. O’Neill, John C. Murray, Charles E. Nolan
Publikováno v:
Journal of Medicinal Chemistry. 58:2678-2702
The identification of centrally efficacious β-secretase (BACE1) inhibitors for the treatment of Alzheimer's disease (AD) has historically been thwarted by an inability to maintain alignment of potency, brain availability, and desired absorption, dis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::455eb0d85337e81623d88cc6b235a8b0
https://doi.org/10.1021/jm501833t
https://doi.org/10.1021/jm501833t
Autor:
Mark W. Bundesmann, David Riddell, Peter Mikochik, Leanne M. Buzon, Brian T. O’Neill, Subas M. Sakya, Jayvardhan Pandit, Christopher Ryan Butler, Xinjun Hou, Ashley Robshaw, Kevin D. Parris, Jason K. Dutra, Ricardo Lira, Loren M. Price, Charles E. Nolan, Elizabeth Mary Beck, Bruce N. Rogers, Gabriela Barreiro, Aijia Yu, Michael Aaron Brodney, Cathleen Gonzales, Erik Alphie Lachapelle, Shawn D. Doran, Luis Martinez-Alsina, Kevin E. Henegar, Ying Fan, Kevin Atchison, Eric F. Johnson, John C. Murray, Kevin Ogilvie, Yong Zhang
Publikováno v:
Journal of Medicinal Chemistry
In recent years, the first generation of β-secretase (BACE1) inhibitors advanced into clinical development for the treatment of Alzheimer’s disease (AD). However, the alignment of drug-like properties and selectivity remains a major challenge. Her
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8005f5cf17b6e63dea10eb5d783b7474
http://europepmc.org/articles/PMC4415909
http://europepmc.org/articles/PMC4415909
Autor:
David Riddell, Ashley Robshaw, H. Zhou, Stacey J. Sukoff Rizzo, Kevin Atchison, Margaret M. Zaleska, Cathleen Gonzales
Publikováno v:
Pharmacology Biochemistry and Behavior. 126:28-35
Development of novel therapeutic agents aimed at treating neurodegenerative disorders such as Alzheimer's and Parkinson's diseases require chronic and preferentially oral dosing in appropriate preclinical rodent models. Since many of these disease mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a463188fad36af1a54f6ec513b09bc35
https://doi.org/10.1016/j.pbb.2014.08.010
https://doi.org/10.1016/j.pbb.2014.08.010
Autor:
Jeffrey W Brulet, Christopher W. am Ende, Michael Aaron Brodney, Sherry Niessen, Brian T. O’Neill, Kevin Atchison, Douglas S. Johnson, Kieran F. Geoghegan, David Riddell, Charles E. Nolan, Elizabeth Mary Beck, Graham M. West, David Karanian, Cheng Chang, Shawn D. Doran, Xinjun Hou, Christopher Houle, Andrea M. Zuhl, Claude Ambroise, Joshua C. Judkins
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-14 (2016)
Nature Communications
Nature Communications
Inhibition of β-secretase BACE1 is considered one of the most promising approaches for treating Alzheimer's disease. Several structurally distinct BACE1 inhibitors have been withdrawn from development after inducing ocular toxicity in animal models,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7b96cd9d34c562c2e27085edae0e78d
https://doi.org/10.1038/ncomms13042
https://doi.org/10.1038/ncomms13042